한국형 양극성 장애 약물치료 알고리듬 2022: 총론
Korean Medication Algorithm Project for Bipolar Disorder 2022: Overview
0
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objectives The pharmacotherapy of bipolar disorder is complex. A treatment guideline or algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was revised through expert consensus on pharmacotherapy for bipolar disorder. Methods We revised the KMAP-BP 2018 questionnaire and conducted a survey of expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. Here, we report the results from KMAP-BP 2022. Results The preferred first-step strategies for acute euphoric mania are a combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. For psychotic mania, an MS and AAP combination, and AAP monotherapy are preferred. For hypomania, MS monotherapy and AAP monotherapy are preferred. The first-step strategies for mild to moderate bipolar depression are MS monotherapy, lamotrigine (LMT) monotherapy, AAP monotherapy, an MS+AAP combination, and an AAP+LMT combination. For non-psychotic severe depression, the MS+AAP combination, the AAP+LMT combination, and the MS+LMT combination are preferred. For psychotic severe depression, MS+AAP and AAP+LMT are preferred. Conclusion We obtained expert consensus and developed KMAP-BP 2022. Compared with KMAP-BP 2018, we can figure out clinicians’ preferences and decisions in real clinical situations more clearly. The preference for AAP increased, and that of MS and an antidepressant decreased. We hope KMAP-BP 2022 is helpful for clinicians who treat patients with bipolar disorder.
Abstract
Objectives The pharmacotherapy of bipolar disorder is complex. A treatment guideline or algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) was revised through expert consensus on pharmacotherapy for bipolar disorder. Methods We revised the KMAP-BP 2018 questionnaire and conducted a survey of expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. Here, we report the results from KMAP-BP 2022. Results The preferred first-step strategies for acute euphoric mania are a combination of a mood stabilizer (MS) and an atypical antipsychotic (AAP), MS monotherapy, and AAP monotherapy. For psychotic mania, an MS and AAP combination, and AAP monotherapy are preferred. For hypomania, MS monotherapy and AAP monotherapy are preferred. The first-step strategies for mild to moderate bipolar depression are MS monotherapy, lamotrigine (LMT) monotherapy, AAP monotherapy, an MS+AAP combination, and an AAP+LMT combination. For non-psychotic severe depression, the MS+AAP combination, the AAP+LMT combination, and the MS+LMT combination are preferred. For psychotic severe depression, MS+AAP and AAP+LMT are preferred. Conclusion We obtained expert consensus and developed KMAP-BP 2022. Compared with KMAP-BP 2018, we can figure out clinicians’ preferences and decisions in real clinical situations more clearly. The preference for AAP increased, and that of MS and an antidepressant decreased. We hope KMAP-BP 2022 is helpful for clinicians who treat patients with bipolar disorder.
참고문헌 (31)
- 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
- 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
- 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
- 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
- Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
- Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
- Woo YS, "Korean medication algorithm project for bipolar disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
- Young Sup Woo, "Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision", Clinical Psychopharmacology and Neuroscience, 16(4), pp.434~448 (2018), 대한정신약물학회[DOI]
- Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, pp.1~104 (2000)
- Yildiz A, "A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania", Psychol Med, 45, pp.299~317 (2015)
- Cipriani A, "Comparative efficacy and acceptability of antimanic drugs in acute mania : a multiple-treatments meta-analysis", Lancet, 378, pp.1306~1315 (2011)
- Song HR, "Current prescription pattern of maintenance treatments for bipolar patients in Korea : a focus on the transition from acute treatments", Psychiatry Clin Neurosci, 70, pp.42~50 (2016)
- Judd LL, "The long-term natural history of the weekly symptomatic status of bipolar I disorder", Arch Gen Psychiatry, 59, pp.530~537 (2002)
- Bartoli F, "Effect of clinical response to active drugs and placebo on antipsychotics and mood stabilizers relative efficacy for bipolar depression and mania:a meta-regression analysis", J Psychopharmacol, 32, pp.416~422 (2018)
- Zagozdzon P, "Mortality rates in users of typical and atypical antipsychotics : a database study in Poland", Drugs Real World Outcomes, 3, pp.345~351 (2016)
- Solmi M, "Safety, tolerability, and risks associated with first- and secondgeneration antipsychotics: a state-of-the-art clinical review", Ther Clin Risk Manag, 13, pp.757~777 (2017)
- Goodwin GM, "Evidence-based guidelines for treating bipolar disorder:revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
- (2014)[URL]
- Yatham LN, "Canadian network for mood and anxiety treatments (CANMAT)and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013", Bipolar Disord, 15, pp.1~44 (2013)
- Solmi M, "Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in shortterm trials", CNS Spectr, 21, pp.403~418 (2016)
- Suttajit S, "Quetiapine for acute bipolar depression : a systematic review and meta-analysis", Drug Des Devel Ther, 8, pp.827~838 (2014)
- Kennedy SH, "Canadian network for mood and anxiety treatments (CANMAT)2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments", Can J Psychiatry, 61, pp.540~560 (2016)
- El-Mallakh RS, "Antidepressants worsen rapid-cycling course in bipolar depression : a STEP-BD randomized clinical trial", J Affect Disord, 184, pp.318~321 (2015)
- Parmentier T, "The use of triiodothyronine (T3) in the treatment of bipolar depression: a review of the literature", J Affect Disord, 229, pp.410~414 (2018)
- Candy M, "Psychostimulants for depression", Cochrane Database Syst Rev, 2, pp.CD006722~ (2008)
- McGirr A, "Clinical efficacy and safety of repetitive transcranial magnetic stimulation in acute bipolar depression", World Psychiatry, 15, pp.85~86 (2016)
- Jeong Seok Seo, "Korean Medication Algorithm for Depressive Disorders 2017: Third Revision", Clinical Psychopharmacology and Neuroscience, 16(1), pp.67~87 (2018), 대한정신약물학회[DOI]
- 민경준, "한국형 양극성 장애 약물치료 알고리듬 2010: 총론", 대한정신약물학회지, 22(3), pp.142~153 (2011), 대한정신약물학회
- 윤보현, "한국형 양극성 장애 약물치료 알고리듬 2010: 다른 치료 지침들과의 비교", 대한정신약물학회지, 22(4), pp.171~182 (2011), 대한정신약물학회
- Culleton B, "Development and limitations of clinical practice guidelines", Methods Mol Biol, 473, pp.251~261 (2009)
- McIntyre JS, "Usefulness and limitations of treatment guidelines in psychiatry", World Psychiatry, 1, pp.186~189 (2002)